Cipla And mAbxience Announce Their Partnership To Provide Essential BioSimilars To South Africa
Cipla And mAbxience Announce Their Partnership To Provide Essential BioSimilars To South Africa. It has been reported that Cipla and mAbxience have partnered in order to provide essential BioSimilars to South Africa. This partnership will focus on Oncology and Respiratory-Related Biosimilars.
This partnership seeks to make sure that both companies continue to provide the high quality medical services to its clients. The companies also aim to make BioSimilars accessible to a lot of people as Oncology treatments can be expensive, thereby excluding a lot of patients. Cipla, established in 1935, is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in its home markets of India, South Africa, North America, and key regulated and emerging markets. Cipla South Africa is one of the largest pharmaceutical companies in South Africa by volume and third largest by value. It is trusted by healthcare professionals and patients across the world.
Over the last 86 years, the company has managed to strengthen its leadership in the pharmaceutical industry and fortified its promise of ‘Caring for Life’. As a responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders.
mAbxience is a high growth international biotechnology company specialized in the research, development, manufacture and global commercialization of biopharmaceutical products to treat and prevent diseases across different therapeutic areas. Both companies are well experienced in the medical filed in that when they combine resources they will be able to make the best Oncology and Respiratory-Related Biosimilars to the South African public.
